For help on how to get the results you want, see our search tips.
67 results
Medicine type
Accelerated assessment Remove Accelerated assessment filter
Additional monitoring Remove Additional monitoring filter
Biosimilar Remove Biosimilar filter
Conditional approval Remove Conditional approval filter
Exceptional circumstances Remove Exceptional circumstances filter
Medicine
Summaries of opinion Remove Summaries of opinion filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Authorisation status
Withdrawn Remove Withdrawn filter
-
List item
Human medicine European public assessment report (EPAR): Iblias
Octocog alfa, Hemophilia A
Date of authorisation: 18/02/2016,
, Revision: 4, Withdrawn, Last updated: 18/02/2020
-
List item
Human medicine European public assessment report (EPAR): Zalmoxis
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Hematopoietic Stem Cell Transplantation; Graft vs Host Disease
Date of authorisation: 18/08/2016,
, Revision: 1, Withdrawn, Last updated: 14/02/2020
-
List item
Human medicine European public assessment report (EPAR): Fexeric
ferric citrate coordination complex, Hyperphosphatemia; Renal Dialysis
Date of authorisation: 23/09/2015,, Revision: 2, Withdrawn, Last updated: 04/02/2020
-
List item
Human medicine European public assessment report (EPAR): Thorinane
enoxaparin sodium, Venous Thromboembolism
Date of authorisation: 14/09/2016,, 
, Revision: 2, Withdrawn, Last updated: 24/10/2019
-
List item
Human medicine European public assessment report (EPAR): Lartruvo
Olaratumab, Sarcoma
Date of authorisation: 09/11/2016,, 
, , Revision: 3, Withdrawn, Last updated: 02/09/2019
-
List item
Human medicine European public assessment report (EPAR): Daklinza
daclatasvir dihydrochloride, Hepatitis C, Chronic
Date of authorisation: 22/08/2014,, Revision: 15, Withdrawn, Last updated: 30/08/2019
-
List item
Human medicine European public assessment report (EPAR): Rituzena (previously Tuxella)
rituximab, Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis
Date of authorisation: 13/07/2017,, , Revision: 7, Withdrawn, Last updated: 08/07/2019
-
List item
Human medicine European public assessment report (EPAR): ATryn
Antithrombin alfa, Antithrombin III Deficiency
Date of authorisation: 28/07/2006,, 
, Revision: 16, Withdrawn, Last updated: 02/07/2019
-
List item
Human medicine European public assessment report (EPAR): Cyltezo
adalimumab, Hidradenitis Suppurativa; Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Juvenile Rheumatoid; Uveitis; Arthritis, Rheumatoid; Colitis, Ulcerative; Spondylitis, Ankylosing
Date of authorisation: 10/11/2017,, , Revision: 2, Withdrawn, Last updated: 06/03/2019
-
List item
Human medicine European public assessment report (EPAR): Solymbic
adalimumab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Hidradenitis Suppurativa; Psoriasis; Arthritis, Rheumatoid
Date of authorisation: 22/03/2017,, , Revision: 2, Withdrawn, Last updated: 05/03/2019
-
List item
Human medicine European public assessment report (EPAR): Lusduna
insulin glargine, Diabetes Mellitus
Date of authorisation: 03/01/2017,, Revision: 2, Withdrawn, Last updated: 22/01/2019
-
List item
Human medicine European public assessment report (EPAR): Raplixa
human fibrinogen, human thrombin, Hemostasis, Surgical
Date of authorisation: 19/03/2015,, Revision: 6, Withdrawn, Last updated: 10/10/2018
-
List item
Human medicine European public assessment report (EPAR): Zinbryta
daclizumab, Multiple Sclerosis
Date of authorisation: 01/07/2016,, Revision: 8, Withdrawn, Last updated: 28/06/2018
-
List item
Human medicine European public assessment report (EPAR): Olysio
simeprevir, Hepatitis C, Chronic
Date of authorisation: 14/05/2014,, Revision: 13, Withdrawn, Last updated: 23/05/2018
-
List item
Human medicine European public assessment report (EPAR): Vibativ
telavancin, Pneumonia, Bacterial; Cross Infection
Date of authorisation: 02/09/2011,, Revision: 10, Withdrawn, Last updated: 16/05/2018
-
List item
Human medicine European public assessment report (EPAR): Evarrest
human fibrinogen, human thrombin, Hemostasis
Date of authorisation: 25/09/2013,, Revision: 4, Withdrawn, Last updated: 03/04/2018
-
List item
Human medicine European public assessment report (EPAR): Ristempa
pegfilgrastim, Neutropenia
Date of authorisation: 13/04/2015,, Revision: 3, Withdrawn, Last updated: 07/03/2018
-
List item
Human medicine European public assessment report (EPAR): Glybera
alipogene tiparvovec, Hyperlipoproteinemia Type I
Date of authorisation: 25/10/2012,, , Revision: 8, Withdrawn, Last updated: 30/10/2017
-
List item
Human medicine European public assessment report (EPAR): Zontivity
vorapaxar sulfate, Myocardial Infarction
Date of authorisation: 19/01/2015,, Revision: 2, Withdrawn, Last updated: 20/09/2017
-
List item
Human medicine European public assessment report (EPAR): Vitekta
elvitegravir, HIV Infections
Date of authorisation: 13/11/2013,, Revision: 4, Withdrawn, Last updated: 29/05/2017
-
List item
Human medicine European public assessment report (EPAR): Biograstim
filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 15/09/2008,, Revision: 8, Withdrawn, Last updated: 19/01/2017
-
List item
Human medicine European public assessment report (EPAR): Incivo
telaprevir, Hepatitis C, Chronic
Date of authorisation: 19/09/2011,, Revision: 19, Withdrawn, Last updated: 06/10/2016
-
List item
Human medicine European public assessment report (EPAR): Rienso
Ferumoxytol, Anemia; Kidney Failure, Chronic
Date of authorisation: 15/06/2012,, Revision: 7, Withdrawn, Last updated: 13/07/2015
-
List item
Human medicine European public assessment report (EPAR): Provenge
autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor, Prostatic Neoplasms
Date of authorisation: 06/09/2013,, Revision: 1, Withdrawn, Last updated: 19/05/2015
-
List item
Human medicine European public assessment report (EPAR): BindRen
colestilan, Hyperphosphatemia
Date of authorisation: 21/01/2013,, Revision: 2, Withdrawn, Last updated: 01/04/2015